Chez HCS Pharma, nous sommes ravis de partager avec vous les avancées significatives que nous avons réalisées dans nos projets de recherche et développement. Avant de commencer, nous tenons à remercier “La Gazette du Laboratoire” pour leur soutien continu et leur couverture détaillée de nos efforts. Notre entreprise, basée à Read more…
We are really pleased to announce that we will be present in BioAsia-Taiwan and present our breakthrough technology BIOMIMESYS alongside our partners Molecular Devices (USA) and LumiSTAR Biotechnology (TW). We are 3 companies in 3 different continents unifying their strenghs to develop the best strategy to find new and more Read more…
After Japan, the business trip has been been continued in Taïwan for several days! As a scientist, I was really happy to see such open-mind spirit when I present BIOMIMESYS technology and how this kind of technology will change the drug discovery process and help the cell therapy/regenerative medicine in Read more…
Currently in Japan, it’s already been a week in Asia. Time goes by very quickly with 3 days of events, many appointments, visits from potential partners, a visit to the Kobe biopark and JETRO, and work appointments with our privileged partner, AS ONE.The 3 days in IDDST 2023 events in Read more…
Nathalie, founder, CEO and CSO of HCS Pharma will be present in BIO international convention that takes place in Boston, USA from the 5th to the 8th of June. Is it the place to be for a start-up like HCS Pharma, proposing a breakthrough technology that will revolutionnize the biotechnology Read more…
I will be pleased to be in BIO-Europe Spring in Basel, Switzerland to present BIOMIMESYS, our breakthrough technology and our new results that we have with it. In HCS Pharma, we are reinventing biology with our academic partners by analyzing the impact of changes in the microenvironment on cells and Read more…
Poster presented during the SLAS event in San Diego on the 27th and 28th of February 2023. Title: BIOMIMESYS® Hydroscaffold, a ready-to-use organ-specific Extracellular Matrix for Relevant Phenotypic Screening Dr. Nathalie Maubon*, Dr. Véronique De Conto, Dr. Méryl Roudaut, Dr Alejandra Mogrovejo – Valdivia, Julien Leriche, Vaihere Cheung and Dr Read more…
During the Healthcare Expo organized that take place in Taïwan between the 30th of November and the 3rd of December, our partner Tokyo Future Style Taiwan had a booth and presented BIOMIMESYS® technology. Dr Dar-Bin Shieh stayed a lot of time with our partner to discuss with Joseph and his Read more…
One week later after our business trip in Asia, we are lucky to welcome Pr Dar Bin Shieh from National Cheng Kung University (Taiwan) in Lille on the 16th of November. In the morning, we have been invited in OncoLille, we have presented all our work in oncology field with Read more…
BIOMIMESYS® is a patented 3D matrix reproducing the physicochemical properties of the extracellular matrix (ECM), different from classical hydrogels used for 3D cell culture. It is composed of native ECM components: Hyaluronic Acid (HA) combined with collagens, adhesion peptides… in the form of a unique hydroscaffold, i.e. exhibiting a dual Read more…
In order to make known BIOMIMESYS technology, Grégory and Nathalie were in Asia in October during one month. The first step was in Japan. We have worked with our partners from AS ONE and JVC Kenwood. We had the opportunity to visit them in AS ONE office in order to Read more…
We are pleased to announce that HCS Pharma secured 20 Million EUR capital commitment from GEM group following the public listing of the company shares on a European stock exchange. We are under the IPO process that we will finalize in the next coming months. The proceeds of IPO with Read more…
We are really pleased to announce that we have officially created a representative office in Taïwan (company 仿生培養技術中心 ID number 90729614) which is directed by our partner, Joseph Chou 周肇隆 ジョーゼフ・チョウ, member of our advisory board. Thanks to Joseph and Professor Szecheng J. Lo, member of our scientific advisory board, all Read more…
Raising funds in Europe when we carry a disruptive technology such as BIOMIMESYS technology which requires substantial financial investment for R&D is not so easy. Fortunately, Europe has understood this well and is helping entrepreneurs in this laborious task. In 2020, we entered the Invest Horizon coaching program. We were Read more…
We are pleased and proud to welcome Dr Philippe Manivet and Dr Anthony Trezeibre in our Scientific Advisory Board. We are developing new innovative projects with them around our BIOMIMESYS technology. Because our BIOMIMESYS technology is requested in different fields and we want to stay at the forefront of innovation, Read more…
Among 370 applications from 54 countries, I am proud to be selected with 9 other start-ups for Female Founder Challenge organized by Vivatechnology & 50inTech. We are to women frmn France. “In Europe, 92% of the funds were invested in startups founded by men. The tech sector needs to be Read more…
Dr. Karine Hannebicque has joined our Scientific Advisory Board. She is a surgeon in breast cancer and reconstructive surgery working in Oscar Lambret Center in the Department of breast oncology since 2013. She is also Medical Coordinator of the Ambulatory Surgery Unit since 2018. After her Internship in Obstetrics & Read more…
We are really happy to welcome Prof. Lo in our Scientific Advisory Board. Prof. Lo has a huge experiment in hepatitis infection and liver diseases with more than 120 publications in this field. With help of Joseph Chou (CEO of Tokyo Future Style Taiwan), Pr Lo leads all R&D programs Read more…
It is now well described that in tumor biopsies, the stiffness of the cancerous tissue is higher than the surrounding non-cancerous tissue of the same organ, with a described remodeling of the ECM. The increase in rigidity is related to the stimulation of fibroblasts that increase the synthesis of glycosaminoglycans, Read more…
Among more than 5,000 applicants from 128 different countries, HCS Pharma has been selected by Hello Tomorrow as one of “Deep Tech Pioneers” from their annual Global Challenge 2020 with our groundbreaking technology BIOMIMESYS®! BIOMIMESYS® is an unique groundbreaking 3D technology that associated the behavior of solid scaffold, by using Read more…
Our CEO, Nathalie is the Chairwoman of the session “ Next Generation High-Content Bioimaging – Phenotypic Discovery” (Track 3 – session 2) at next SLAS Barcelona event. This event will bring together more than 1,000 scientists and technologists from around the world. The theme for the 2019 Europe Conference is Read more…
We are very happy to wish you a wonderful year 2019!
Nous sommes très heureux de vous souhaiter une excellente année 2019 !
The 20th International Congress on In Vitro Toxicology (ESTIV2018) is coming and it will be a great occasion for HCS-Pharma to showcase our current co-development, with the institute du thorax of Nantes and the RHU CHOPIN, on the use of hepatocyte-like cells differentiated from human induced pluripotent stem cells (hiPSC) Read more…